GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, Inc. (NASDAQ: GDRX), America's leading resource for healthcare savings, today announced the closing of the acquisition of HealthiNation as part of the company's continued investment in vital health information and consumer resources to help Americans navigate the complex world of healthcare. HealthiNation offers a comprehensive library of thousands of premium videos on a wide range of health topics that provide a platform for pharmaceutical manufac

GoodRx Expands Manufacturer Solutions Offering with Acquisition of HealthiNation

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings Inc. (Nasdaq: GDRX), America's leading resource for healthcare savings, today announced it will release its first quarter 2021 financial results after U.S. markets close on Thursday, May 13, 2021. GoodRx management will hold a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook. Prior to the call, GoodRx will issue a press release containing a link

GoodRx Announces Date for First Quarter 2021 Earnings Release and Conference Call

Skillz

Teladoc

These three growth stocks are down big. The decline in stock price could mean a great buying opportunity for long-term investors.

3 Growth Stocks That Could Be Great Long-Term Investments

GoodRx is a free-to-use platform that sources discounts on prescription drugs for patients in the US. The business is growing its user base, which is powering expansion into telehealth and subscription services.

GoodRx: Understanding This Misunderstood Disruptor

DoorDash

Palantir Technologies

Snowflake

Unity Software

After a handful of companies had their initial public offering (IPO), let's take a deeper look at each of their first quarterly reports. The post These 5 Hot IPOs Post Weak Q4 Results appeared first on InvestorPlace.

These 5 Hot IPOs Post Weak Q4 Results

Some of the drug discounter's growth is out of the company's hands.

Can GoodRx Bounce Back From Its Pandemic Slowdown?

GoodRx Q4 earnings and FY2021 forecast continued to validate the strong core of the company and foreshadowed the future revenue drivers. The primary prescription business is a steady and growing cash cow that provides a strong valuation floor.

GoodRx: A Doctor's Prescription For Your Growth Portfolio

This healthcare tech company has helped consumers save a cumulative $25 billion on prescription drugs. But that doesn't necessarily make its stock a buy.

Could GoodRx Be a Millionaire-Maker Stock?

Poshmark

Lordstown Motors

Investors aren't seeing the results that they'd hoped for from these newcomers to the public markets.

Despite More Stock Market Records, These 3 IPO Stocks Got Crushed Friday

Revenue was ahead of expectations, but investors can't shake this massive net loss.

Why GoodRx Holdings Stock Got Crushed Today

Prescription transaction volume fueled strong revenue growth for the healthcare company in Q4.

GoodRx Q4 Update: Solid Growth, Weak Guidance

GoodRx Holdings' (GDRX) Management on Q4 2020 Results - Earnings Call Transcript

Shares of GoodRx Holdings Inc. fell more than 3% in the extended session Thursday after the health-care company reported adjusted earnings that were above Wall Street expectations but guided for lower first-quarter sales. GoodRx said it lost $298.3 million, or 74 cents a share, in the fourth quarter, contrasting with earnings of $15.2 million, or 4 cents a share, in the fourth quarter of 2019.

GoodRx stock dips after lower-than-expected quarterly guidance

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings Inc. (Nasdaq: GDRX), America's leading resource for healthcare savings, has released its fourth quarter and full year 2020 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com. GoodRx management will host a conference call and webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook. Fourt

GoodRx Releases Fourth Quarter and Full Year 2020 Financial Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, America's leading resource for healthcare savings, has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2021. The list honors the businesses that have not only found a way to be resilient in the past year, but also turned those challenges into impact-making processes. GoodRx is ranked #3 in the Health category for its commitment to delivering innovative solutions that give Americans greater access to

GoodRx Named to Fast Company's 2021 List of the World's Most Innovative Companies

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, America's leading source for healthcare savings, today launched GoodRx Helps, a philanthropic initiative that provides free prescriptions and care to patients in need. For the program's first effort, GoodRx has partnered with the National Association of Free and Charitable Clinics (NAFC) to provide free medications to those who are unable to afford healthcare due to systemic barriers. In connection with the company's recent initial public offering,

GoodRx Launches GoodRx Helps, a $40+ Million Charitable Initiative to Help Improve Healthcare for Americans Who Need It Most

FS Development Corp. II

SPAC-mania is in full swing, and the healthcare sector is starting to pop with new offerings.

2 New Healthcare SPACs Worth Adding to Your Watch List

American Well Corporation

Inari Medical

How have these big healthcare IPOs been doing?

A Look at GoodRx, Inari, and Amwell

BlackLine

Block

These technology companies are growing like gangbusters.

3 High-Growth Tech Stocks That Could Be 10-Baggers

New York, New York--(Newsfile Corp. - February 16, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of GoodRx Holdings, Inc (NASDAQ: GDRX) alleging that the Company violated federal securities laws.Class Period: September 23, 2020 and November 16, 2020Lead Plaintiff Deadline: February 16, 2021Learn more about your recoverable losses in GDRX:

GDRX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 16, 2021 in the Class Action Filed on Behalf of GoodRx Holdings, Inc Limited Shareholders

NEW YORK, Feb. 16, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the "Class Period"), of the important February 16, 2021...

GDRX FINAL DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages GoodRx Holdings, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline Today - GDRX

LOS ANGELES, Feb. 16, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ: GDRX) for violations of §§10(b) and 20(a) of the Securities...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against GoodRx Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - February 16, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against GoodRx Holdings, Inc. (NASDAQ: GDRX) ("GoodRx" or "the Company") and certain of its officers, on behalf of shareholders who purchased or otherwise acquired GoodRx securities between September 23, 2020 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by...

GDRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds GoodRx Holdings, Inc. Investors of Class Action and Lead Plaintiff Deadline: February 16, 2021

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX) and certain of its officers. The class action, filed in United States District Court for the Central District of California, and docketed under 21-cv-00175, is on behalf of a class consisting of...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in GoodRx Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline - GDRX

New York, New York--(Newsfile Corp. - February 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of GoodRx Holdings, Inc ("GoodRx ") (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of GoodRx Holdings, Inc of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 16, 2021 - GDRX

News for GoodRx Holdings Stock (GDRX)